443 related articles for article (PubMed ID: 31833593)
21. HER-2/neu-derived peptide epitopes are also recognized by cytotoxic CD3(+)CD56(+) (natural killer T) lymphocytes.
Baxevanis CN; Gritzapis AD; Tsitsilonis OE; Katsoulas HL; Papamichail M
Int J Cancer; 2002 Apr; 98(6):864-72. PubMed ID: 11948464
[TBL] [Abstract][Full Text] [Related]
22. T cell receptor V beta 2 and V beta 6 mediate tumor-specific cytotoxicity by tumor-infiltrating lymphocytes in ovarian cancer.
Peoples GE; Davey MP; Goedegebuure PS; Schoof DD; Eberlein TJ
J Immunol; 1993 Nov; 151(10):5472-80. PubMed ID: 8228239
[TBL] [Abstract][Full Text] [Related]
23. γδ T cell activation by bispecific antibodies.
Oberg HH; Kellner C; Gonnermann D; Peipp M; Peters C; Sebens S; Kabelitz D; Wesch D
Cell Immunol; 2015 Jul; 296(1):41-9. PubMed ID: 25979810
[TBL] [Abstract][Full Text] [Related]
24. Identification of a regulatory Vδ1 gamma delta T cell subpopulation expressing CD73 in human breast cancer.
Chabab G; Barjon C; Abdellaoui N; Salvador-Prince L; Dejou C; Michaud HA; Boissière-Michot F; Lopez-Crapez E; Jacot W; Pourquier D; Bonnefoy N; Lafont V
J Leukoc Biol; 2020 Jun; 107(6):1057-1067. PubMed ID: 32362028
[TBL] [Abstract][Full Text] [Related]
25. In vitro stimulation of ovarian tumour-associated lymphocytes with a peptide derived from HER2/neu induces cytotoxicity against autologous tumour.
Linehan DC; Peoples GE; Hess DT; Summerhayes IC; Parikh AS; Goedegebuure PS; Eberlein TJ
Surg Oncol; 1995 Feb; 4(1):41-9. PubMed ID: 7780612
[TBL] [Abstract][Full Text] [Related]
26. Accumulation of gamma/delta T cells in human dysgerminoma and seminoma: roles in autologous tumor killing and granuloma formation.
Zhao X; Wei YQ; Kariya Y; Teshigawara K; Uchida A
Immunol Invest; 1995 May; 24(4):607-18. PubMed ID: 7622197
[TBL] [Abstract][Full Text] [Related]
27. Co-expression patterns of chimeric antigen receptor (CAR)-T cell target antigens in primary and recurrent ovarian cancer.
Banville AC; Wouters MCA; Oberg AL; Goergen KM; Maurer MJ; Milne K; Ashkani J; Field E; Ghesquiere C; Jones SJM; Block MS; Nelson BH
Gynecol Oncol; 2021 Feb; 160(2):520-529. PubMed ID: 33342620
[TBL] [Abstract][Full Text] [Related]
28. Lymphocytes infiltrating ovarian malignant ascites: modulation of IL-2-induced proliferation by IL-4 and of selective increase in CD8+ T cells by TNF-alpha.
Ioannides CG; Rashed S; Fisk B; Fan D; Itoh K; Freedman RS
Lymphokine Cytokine Res; 1991 Aug; 10(4):307-15. PubMed ID: 1932375
[TBL] [Abstract][Full Text] [Related]
29. Lymphocytes infiltrating human ovarian tumors. I. Role of Leu-19 (NKH1)-positive recombinant IL-2-activated cultures of lymphocytes infiltrating human ovarian tumors.
Heo DS; Whiteside TL; Kanbour A; Herberman RB
J Immunol; 1988 Jun; 140(11):4042-9. PubMed ID: 3286766
[TBL] [Abstract][Full Text] [Related]
30. Killing of laminin receptor-positive human lung cancers by tumor infiltrating lymphocytes bearing gammadelta(+) t-cell receptors.
Ferrarini M; Heltai S; Pupa SM; Mernard S; Zocchi R
J Natl Cancer Inst; 1996 Apr; 88(7):436-41. PubMed ID: 8618235
[TBL] [Abstract][Full Text] [Related]
31. [The comparison of biological characteristics between tumor-infiltrating lymphocytes and tumor-associated lymphocytes in ascites of epithelial ovarian carcinoma].
Kang S; Shen K; Lang J
Zhonghua Fu Chan Ke Za Zhi; 1998 Oct; 33(10):607-10. PubMed ID: 10806687
[TBL] [Abstract][Full Text] [Related]
32. Distribution and functions of γδ T cells infiltrated in the ovarian cancer microenvironment.
Chen X; Shang W; Xu R; Wu M; Zhang X; Huang P; Wang F; Pan S
J Transl Med; 2019 May; 17(1):144. PubMed ID: 31064389
[TBL] [Abstract][Full Text] [Related]
33. Characterization of T-cell receptor V beta repertoire in ovarian tumour-reacting CD3+ CD8+ CD4- CTL lines.
Fisk B; Flytzanis CN; Pollack MS; Wharton JT; Ioannides CG
Scand J Immunol; 1994 Dec; 40(6):591-600. PubMed ID: 7848491
[TBL] [Abstract][Full Text] [Related]
34. Tissue-Specific Expression of TIGIT, PD-1, TIM-3, and CD39 by γδ T Cells in Ovarian Cancer.
Weimer P; Wellbrock J; Sturmheit T; Oliveira-Ferrer L; Ding Y; Menzel S; Witt M; Hell L; Schmalfeldt B; Bokemeyer C; Fiedler W; Brauneck F
Cells; 2022 Mar; 11(6):. PubMed ID: 35326415
[TBL] [Abstract][Full Text] [Related]
35. Combination therapy with B7H3-redirected bispecific antibody and Sorafenib elicits enhanced synergistic antitumor efficacy.
Huang C; Li H; Feng Y; Li X; Zhang Z; Jiang C; Wang J; Yang C; Fu Y; Mu M; Zhao S; Wang Z; Kuang Y; Hou H; Wang Y; Guo W; Xu J; Yang H; Zhou L; Tong A; Guo G
Theranostics; 2020; 10(23):10498-10512. PubMed ID: 32929362
[No Abstract] [Full Text] [Related]
36. Phenotype, cytokine production and cytolytic capacity of fresh (uncultured) tumour-infiltrating T lymphocytes in human renal cell carcinoma.
Van den Hove LE; Van Gool SW; Van Poppel H; Baert L; Coorevits L; Van Damme B; Ceuppens JL
Clin Exp Immunol; 1997 Sep; 109(3):501-9. PubMed ID: 9328129
[TBL] [Abstract][Full Text] [Related]
37. Induction of tumor-specific cytotoxicity in tumor infiltrating lymphocytes by HPV16 and HPV18 E7-pulsed autologous dendritic cells in patients with cancer of the uterine cervix.
Santin AD; Bellone S; Palmieri M; Bossini B; Roman JJ; Cannon MJ; Bignotti E; Canè S; Pecorelli S
Gynecol Oncol; 2003 May; 89(2):271-80. PubMed ID: 12713991
[TBL] [Abstract][Full Text] [Related]
38. Selective recruitment of γδ T cells by a bispecific antibody for the treatment of acute myeloid leukemia.
Ganesan R; Chennupati V; Ramachandran B; Hansen MR; Singh S; Grewal IS
Leukemia; 2021 Aug; 35(8):2274-2284. PubMed ID: 33526858
[TBL] [Abstract][Full Text] [Related]
39. Bifunctional iRGD-anti-CD3 enhances antitumor potency of T cells by facilitating tumor infiltration and T-cell activation.
Zhou S; Meng F; Du S; Qian H; Ding N; Sha H; Zhu M; Yu X; Wang L; Liu B; Wei J
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33986122
[TBL] [Abstract][Full Text] [Related]
40. Enhanced killing of primary ovarian cancer by retargeting autologous cytokine-induced killer cells with bispecific antibodies: a preclinical study.
Chan JK; Hamilton CA; Cheung MK; Karimi M; Baker J; Gall JM; Schulz S; Thorne SH; Teng NN; Contag CH; Lum LG; Negrin RS
Clin Cancer Res; 2006 Mar; 12(6):1859-67. PubMed ID: 16551871
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
